Gliomas represent the most common primary brain tumor of the CNS. Resection, radiation therapy, and chemotherapy remain the standard treatment. Isocitrate dehydrogenase 1 or 2 (IDH1 and IDH2, respectively) mutations are frequently expressed in historically defined grade II and III gliomas. Gliomas with IDH mutations display a more indolent disease course and favorable prognosis compared with their wild-type counterparts; however, these tumors usually recur. Considering that mutant IDH is an early oncogenic driver as well as a neoantigen found exclusively and uniformly in nearly all tumor cells and otherwise absent in normal tissues, the IDH mutation represents an ideal therapeutic target.

Immunotherapy has emerged as a promising approach for treating aggressive solid tumors, even within the CNS. Mutation in the metabolic gene isocitrate dehydrogenase 1 (IDH1) represents not only a major glioma defining biomarker but also an attractive therapeutic neoantigen. As patients with IDH-mutant glioma enter early-phase vaccine and immune checkpoint inhibitor clinical trials, there is emerging evidence that implicates the oncometabolite, 2-hydroxyglutarate (2HG), generated by the neomorphic activity of mutant IDH, as a potential barrier to current immunotherapeutic approaches. Here, the authors review the immunomodulatory and immunosuppressive roles of 2HG within the unique IDH-mutant glioma tumor immune microenvironment and discuss promising immunotherapeutic approaches currently being investigated in preclinical models.

Immunotherapy for IDH-Mutant Glioma: Clinical Studies

**IDH Peptide Vaccination**

Three different IDH1-R132H–specific peptide vaccines are currently being tested in 4 clinical trials (Table 1), one of which recently released results (ClinicalTrials.gov identifier no. NCT02454634). In 2021, Platten and colleagues reported a phase I trial showing that a 20–amino acid peptide vaccine spanning the mutated region was ca-

**KEYWORDS** glioma; isocitrate dehydrogenase; 2-hydroxyglutarate; immunosuppression; tumor immune microenvironment; IDH; immunology
Richardson et al.

A Brief Overview

Currently, there are a total of 6 ongoing clinical trials targeting programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) exclusively in patients with recurrent IDH-mutant glioma (Table 1). There is a relative dearth of knowledge surrounding the responsiveness of IDH-mutant tumors to ICI since, to date, most brain tumor clinical trial data reflect activity in glioblastoma (GBM), IDH–wild-type disease.45 Despite the recent negative phase III results in GBM from the ICT “CheckMate” trials, IDH-mutant glioma patients have entered the ICI space. The rationale for the use of ICIs in patients with recurrent IDH-mutant glioma is based on data suggesting that alkylating agents such as temozolomide and lomustine promote the emergence of a hypermutated phenotype.59 Heavily treated glial tumors often reach a hypermutant phenotype,60 and the resulting high tumor mutational burden (TMB) may improve responsiveness to ICI.7 Of the 6 trials, 4 trials are currently recruiting, 1 is active, and 1 is complete. The recently completed phase II trial (ClinicalTrials.gov identifier no. NCT02968940) investigated the concurrent administration of a PD-L1 inhibitor (avelumab) with hypofractionated radiation therapy in patients with recurrent grade IV IDH-mutant glioma.

The Immune Landscape of Mutant IDH: A Brief Overview

The tumor immune microenvironment (TIME) in glioma is a complex milieu of various noncancerous cell types and components that include infiltrating immune cells, fibroblasts, endothelial cells, and extracellular matrix.11 It is well appreciated that the immune contexture, specifically the immune cell type, density, localization, orientation, and functional status, all play a significant role in disease progression and influence the efficacy of immune-based therapies.12 Tumor immunology in the brain is unique. Bulk sequencing studies comparing the host immune responses across various cancer types have defined gliomas as “lymphocyte depleted” and/or “immunologically quiet” tumors.13 Since the prioritization of molecular features in the classification of gliomas,1 growing evidence suggests that IDH mutations influence this immunologically “cold”
tumor phenotype. Recent advances in high-dimensional immune profiling techniques such as single-cell RNA sequencing, mass cytometry, and multiplexed immunohistochemistry (IHC) have allowed researchers to gain an even more granular picture of the similarities and differences of the immune contexture between IDH-mutant and IDH–wild-type gliomas.

Several studies have demonstrated that IDH mutations in glioma are associated with less infiltration of CD3+, CD4+, and CD8+ T cells in comparison with their wild-type counterparts. In addition to effector T-cell subsets, our group recently showed a significant reduction in suppressive regulatory T cells (Tregs) in IDH-mutant tumors. In an investigation of a large cohort of diffuse glioma, Berghoff and colleagues showed that the expression of PD-L1, an immunosuppressive cell surface molecule that downregulates T-cell activity, was significantly reduced in IDH-mutant tumors. Recent work by Friebel et al. and Mathewson et al. further interrogated the transcriptional profiles of tumor-infiltrating T cells and compared their activation states between IDH mutational status. Their work demonstrated stronger antitumor immunity in IDH–wild-type GBM compared with IDH-mutant glioma based on single-cell profiling of CD8+ and CD4+ T cells and their respective cytotoxicity/interferon signatures. Given the potential predictive value of tumor-infiltrating lymphocytes and PD-L1 expression for responsiveness to ICI, these data suggest that untreated tumors harboring IDH mutations are inferior responders to ICI compared with IDH–wild-type gliomas based on their “colder” phenotype.

In a separate study focusing on CD68+ tumor-associated macrophages/microglia, Klemm et al. used multiplexed IHC to reveal a greater proportion of tumor-resident microglia (MG) in IDH-mutant tumors, whereas IDH–wild-type tumors were more heavily infiltrated with monocyte-derived macrophages (MDMs). In addition, single-cell profiling of both MG and MDM populations demonstrated a more complex and multifaceted phenotype than the classic M1 versus M2 phenotype, with distinct transcriptional signatures that largely aligned with the tumor’s IDH mutational status. Infiltration of myeloid cells, which are predominantly immunosuppressive, is generally linked to a poorer prognosis in glioma. IDH-mutant tumors exhibit less myeloid cell infiltration compared with their wild-type counterpart, which may explain their more indolent disease course; however, there is no evidence to point specifically to this hypothesis. The distorted immune infiltrate, activation states, and overall tumor immunogenicity unique to mutant disease may play a role in driving response to standard therapy and their prognostic profile. Growing knowledge of the specific characteristics of the IDH-mutant TIME may help define a more delineated immune modulatory approach for this subset of patients.

Differences in the immune cell composition of IDH-mutant tumors may be largely driven by the accumulation of the oncometabolite, 2HG, produced by the neomorphic activity of the mutant IDH enzyme. 2HG has been implicated in reprogramming the glioma cell transcriptome by competitively inhibiting key α-ketoglutarate–depend-
activates T-cell effector functions.\textsuperscript{25} With the use of an IDH inhibitor in various tumor models, the authors were able to demonstrate that 2HG dampened antitumor T-cell immunity induced by IDH1-R132H peptide vaccination and PD-1 inhibition. Infiltrating MDMs were also paracrine targets of 2HG. Friedrich et al. demonstrated that 2HG reprogrammed MDMs toward an immunosuppressive phenotype by altering tryptophan-related metabolic pathways.\textsuperscript{27} 2HG led to the increased uptake/degradation of L-tryptophan and activity of cytoplasmic aryl hydrocarbon receptor (AhR), a key transcription factor that is known to polarize MDMs toward an immunosuppressive phenotype. This work showed that 2HG caused the increased activation of AhR signaling, which resulted in the elevated secretion of interleukin-10 (IL-10) and transforming growth factor-β, two known immunosuppressive molecules that can decrease T-cell activation and proliferation. Furthermore, 2HG also lowered the expression of costimulatory molecules CD80 and CD86 and major histocompatibility complex class II (MHC-II), which reduced the capacity for optimal antigen presentation further driving a tolerogenic phenotype in MDMs. The authors also noted that 2HG-induced T-cell suppression required both the 2HG-mediated uptake of L-tryptophan and functioning AhR in MDMs. While an IDH inhibitor partially restored MDM antigen presentation in mice bearing IDH-mutant tumors, the use of an AhR inhibitor significantly reversed the 2HG-mediated immunosuppressive phenotype in MDMs.\textsuperscript{27} These data not only demonstrate a dual immunomodulatory mechanism of immune evasion mediated by the production of 2HG (Fig. 2) but also suggest that IDH-mutant gliomas are potentially more resistant to immunotherapeutic approaches.

**Mutant IDH Inhibition: Critical to the Immunotherapeutic Strategy?**

The studies above support the use of specific inhibitors of IDH to reverse 2HG-mediated immune suppression, which may improve the efficacy of immunotherapy in patients with IDH-mutant gliomas. Since the discovery of IDH, much effort has been aimed at developing clinical-grade inhibitors specifically targeting mutant IDH1 or IDH2 with the belief that IDH-mutant gliomas are biologically reliant on 2HG as an oncogenic driver. Patients with acute myeloid leukemia and cholangiocarcinoma harboring mutant IDH have had objective responses,\textsuperscript{28,29} which has led to IDH-inhibitor approval from the US FDA. However, the efficacy of these inhibitors as a monotherapy in glioma patients remains unproven. With growing evidence that 2HG acts as an immunosuppressive molecule in glioma, perhaps the focus should shift from a monotherapy to uncovering the utility of inhibitors as a sensitizing agent for immune-based approaches for IDH-mutant tumors.

Promising data from an ongoing phase I clinical trial
Richardson et al. in patients with recurrent low-grade gliomas reported at the 2020 American Association for Cancer Research Annual Meeting suggested that IDH inhibition with ivosidenib (AG-120) or vorasidenib (AG-881) reverses 2HG-mediated immune suppression and may sensitize IDH-mutant gliomas for ICI therapy. Lu et al. measured infiltrating T cells, MDMs/MG, and PD-L1 expression in paired pre- and posttreatment samples. Using IHC and TCR sequencing, they found that inhibition of mutant IDH increased the number of total CD3+ and CD8+ T cells, TCR clones, and TCR diversity. Using RNA sequencing, they also observed a polarization toward a proinflammatory tumor-associated macrophage/microglia signature as well as an increase in PD-L1 expression after treatment. These data are consistent with recently published preclinical data in which an increase in PD-L1 expression was observed in mice bearing IDH-mutant gliomas after IDH inhibition. Although these data support the idea that IDH inhibition may improve the efficacy of immune-based approaches for IDH-mutated glioma, additional studies are needed to validate these observations as well as address the concern of other barriers, such as immunosuppressive mediators and infiltrate. Of the active immunotherapy clinical trials for IDH-mutant glioma, a phase II study (ClinicalTrials.gov identifier no. NCT04056910) led by investigators at the University of Pittsburgh Medical Center is the only trial investigating the combination of a PD-1 inhibitor (nivolumab) with IDH inhibition (ivosidenib).

**Novel Immunotherapeutic Strategies for IDH-Mutant Gliomas: Preclinical Models**

The notion that IDH inhibition should be integrated into immunotherapy for patients with IDH-mutant glioma is based on preclinical studies that have demonstrated successful results incorporating an inhibitor with either vaccination or ICI in mice bearing IDH-mutant tumors (Table 2). To date, preclinical immunotherapeutic strategies that have incorporated IDH inhibition fall into two categories.

**Vaccine With IDH Inhibition**

Kohanbash et al. utilized a vaccine strategy using a combination of synthetic peptides derived from glioma-associated antigens. They demonstrated that after vaccination, mice challenged with IDH-mutant tumors receiving daily treatment of an IDH inhibitor (IDH-35) survived...
TABLE 2. Overview of novel immune-based approaches with an IDH inhibitor in preclinical models

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Engineered IDH-Mutant Mouse Model</th>
<th>Treatment Regimen†</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kadiyala et al., 202115</td>
<td>shp53/shATRX/miIDH1R132H</td>
<td>± Anti–PD-L1 ± IR ± TMZ ± *AGI-5198</td>
<td>Complete tumor regression in 60% of mice when IDHi was combined w/ SOC &amp; checkpoint blockade; reversed immunosuppressive phenotype of infiltrating myeloid cells</td>
</tr>
<tr>
<td>Bunse et al., 201815</td>
<td>GL261-transduced IDH1R132H</td>
<td>± Anti–PD-1 ± *BAY1436032</td>
<td>Enhanced efficacy of checkpoint inhibition w/ IDHi; adoptive transfer of vaccine-induced T cells reduced tumor growth only w/ IDHi</td>
</tr>
<tr>
<td>Kohanbash et al., 201715</td>
<td>GL261-transduced IDH1R132H</td>
<td>± Peptide vaccine ± *IDH-C35</td>
<td>Enhanced efficacy of vaccine w/ IDHi; increased intratumoral CD8+ T cells</td>
</tr>
</tbody>
</table>

IR = irradiation; SOC = standard of care; ± = with or without.
† Drug names following the asterisks denote the particular IDH inhibitor used in the study.

significantly longer than mice with IDH-mutant tumors in the control group. Bunse et al. demonstrated that adoptive transfer of T cells generated from C57BL/6J mice vaccinated with IDH1-R132H peptide vaccine reduced tumor growth in GL261-IDH-mutant Rag-2 knockout mice only when combined with an IDH inhibitor (BAY1436032).15 Together these studies illustrate the potential role of IDH inhibition in improving vaccine efficacy in IDH-mutant glioma.

Checkpoint Blockade With IDH Inhibition

In preclinical models, the combination of an IDH inhibitor with PD-1 blockade resulted in an increase in overall survival in mice harboring IDH-mutant gliomas compared with PD-1 blockade alone.25 In a separate study, Kadiyala et al. targeted the ligand of PD-1 by blocking PD-L1 in mice with IDH-mutant glioma.31 The authors showed that mice bearing IDH-mutant tumors treated with PD-L1 blockade + IDH inhibitor + standard-of-care therapy survived longer compared with IDH inhibitor + standard-of-care therapy. Similarly, Friedrich et al. also inhibited PD-L1 but did not directly mitigate 2HG-mediated immune suppression using an IDH inhibitor and instead used an AhR inhibitor to target 2HG-mediated immune suppression in MDMs.27 They demonstrated that the combination of an AhR inhibitor with PD-L1 blockade resulted in an increase in overall survival in mice harboring IDH-mutant gliomas compared with PD-L1 blockade alone, suggesting that reversal of the 2HG-mediated MDMs immunosuppressive phenotype augments PD-L1 blockade to promote antitumor immunity in IDH-mutant glioma. The aforementioned studies all highlight the potential importance of reversing 2HG-mediated immunosuppressive mechanisms, which may enhance the efficacy of immunomodulatory therapies such as vaccines and ICI in IDH-mutant glioma (Table 2).

Discussion

Phase I clinical data have demonstrated that IDH-mutant peptide vaccination is safe and immunogenic in humans. Despite the promising data and support for further development of this platform, several questions remain. Is the presence of 2HG in the tumor microenvironment of these patients counterproductive to the induction of T-cell immunity? What is the immune contexture at progressive stages? If the IDH1-R132H mutation is an early oncogenic event in gliomagenesis and possesses human leukocyte antigen–restricted immunogenicity against this ubiquitously expressed neoantigen, how do these tumor cells evade immune surveillance in the CNS? Growing evidence suggests the production of 2HG plays an immunosuppressive role in tumor development and recurrence.

Current vaccine and ICI therapy for IDH-mutant glioma may be hindered by 2HG suppressing T-cell responses both directly and indirectly. Manipulation of 2HG using small-molecule IDH inhibitors may augment antitumor immunity by sensitizing the TIME for optimal T-cell cytotoxicity. Once T cells are reinvigorated and/or induced to infiltrate the tumor through IDH inhibition, their activity may be mitigated by the potential resurgence of myeloid-derived suppressor cells and Tregs as well as other immunosuppressive mediators such as indoleamine 2,3-dioxygenase, arginase, TGF-β, and IL-10. Future studies examining the role of IDH inhibition on other aspects of immune contexture are needed. Although IDH inhibition may enhance the efficacy of immune-based therapies, they may result in the opposite effect for other promising targeted therapies that rely on 2HG-generated vulnerabilities such as poly(ADP-ribose) polymerase and nicotinamide phosphoribosyltransferase inhibitors.32,33

In the context of IDH–wild-type glioma, identifying predictive biomarkers and monitoring of immune responses have been limited. For all cancers, TMB is believed to be a strong correlate with the level of preexisting antitumor immunity and responsiveness to ICI.7 In June 2020, the FDA granted approval for pembrolizumab (anti–PD-1) for any solid tumor with high TMB, characterized as having ≥ 10 mutations per megabase.34 As more patients with IDH-mutant glioma enter early-phase immunotherapy clinical trials, a concerted effort should be made to evaluate predictive biomarkers specific for IDH-mutant patients, as their responsiveness is likely different from that of IDH–wild-type tumors. Growing evidence suggests that the intratumoral topography or spatial information between immune cell types may be informative as a potential biomarker for immunotherapy.35
Conclusions

Malignant gliomas harboring IDH mutations represent a unique opportunity for therapeutic targeting. The IDH mutation drives a distorted, immunologically quiescent glioma phenotype. This is largely driven by the production of 2HG, an immunosuppressive molecule working in a “dual” direct and indirect fashion to dampen T-cell responses. Patients with IDH-mutant glioma are entering immunotherapy clinical trials. Immune profiling at baseline and in response to these agents may identify predictive biomarkers for this class of gliomas. Immunotherapies for IDH-mutant glioma may be augmented by abrogating 2HG-mediated immune suppression using an IDH inhibitor.

Acknowledgments

This work was supported by the Jenny Fund (www.thejennyfund.org) and A Shot For Life (www.ashotforlife.org).

References


Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Curry, Richardson, Choi. Acquisition of data: Richardson, Miller, Kitagawa. Analysis and interpretation of data: Curry, Richardson, Miller, Kitagawa, Choi. Drafting the article: Richardson. Critically revising the article: all authors. Reviewed submitted version of manuscript: Curry, Richardson, Miller, Wakimoto, Choi. Administrative/technical/material support: Richardson, Kitagawa. Study supervision: Curry, Choi.

Correspondence
William T. Curry: Massachusetts General Hospital, Boston, MA. wcurry@mgh.harvard.edu.